JP2021517119A5 - - Google Patents

Info

Publication number
JP2021517119A5
JP2021517119A5 JP2020546331A JP2020546331A JP2021517119A5 JP 2021517119 A5 JP2021517119 A5 JP 2021517119A5 JP 2020546331 A JP2020546331 A JP 2020546331A JP 2020546331 A JP2020546331 A JP 2020546331A JP 2021517119 A5 JP2021517119 A5 JP 2021517119A5
Authority
JP
Japan
Prior art keywords
use according
adenovirus
combination
inhibitor
cdk4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020546331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517119A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/000067 external-priority patent/WO2019170283A1/en
Publication of JP2021517119A publication Critical patent/JP2021517119A/ja
Publication of JP2021517119A5 publication Critical patent/JP2021517119A5/ja
Priority to JP2024186627A priority Critical patent/JP2025013934A/ja
Pending legal-status Critical Current

Links

JP2020546331A 2018-03-05 2019-03-05 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 Pending JP2021517119A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024186627A JP2025013934A (ja) 2018-03-05 2024-10-23 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18000210 2018-03-05
EP18000210.7 2018-03-05
PCT/EP2019/000067 WO2019170283A1 (en) 2018-03-05 2019-03-05 Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024186627A Division JP2025013934A (ja) 2018-03-05 2024-10-23 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置

Publications (2)

Publication Number Publication Date
JP2021517119A JP2021517119A (ja) 2021-07-15
JP2021517119A5 true JP2021517119A5 (cg-RX-API-DMAC7.html) 2022-03-14

Family

ID=61569019

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546331A Pending JP2021517119A (ja) 2018-03-05 2019-03-05 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置
JP2024186627A Pending JP2025013934A (ja) 2018-03-05 2024-10-23 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024186627A Pending JP2025013934A (ja) 2018-03-05 2024-10-23 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置

Country Status (13)

Country Link
US (1) US20210038661A1 (cg-RX-API-DMAC7.html)
EP (1) EP3762004B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021517119A (cg-RX-API-DMAC7.html)
KR (2) KR20210031852A (cg-RX-API-DMAC7.html)
CN (1) CN112533620B (cg-RX-API-DMAC7.html)
AU (1) AU2019232768B2 (cg-RX-API-DMAC7.html)
CA (1) CA3092907A1 (cg-RX-API-DMAC7.html)
DK (1) DK3762004T3 (cg-RX-API-DMAC7.html)
ES (1) ES2965632T3 (cg-RX-API-DMAC7.html)
FI (1) FI3762004T3 (cg-RX-API-DMAC7.html)
HU (1) HUE064471T2 (cg-RX-API-DMAC7.html)
SG (1) SG11202007873VA (cg-RX-API-DMAC7.html)
WO (1) WO2019170283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021044061A1 (en) * 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
KR102341347B1 (ko) * 2019-11-28 2021-12-20 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
EP4578943A4 (en) * 2022-08-25 2026-02-25 Fujifilm Corp PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
PL219321B1 (pl) * 2002-10-15 2015-04-30 Per Sonne Holm Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny
WO2005052143A2 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
WO2012022496A2 (en) * 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
US9271988B2 (en) * 2011-07-01 2016-03-01 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer
SG11201507393TA (en) * 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
AU2014272695B2 (en) * 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途

Similar Documents

Publication Publication Date Title
Liu et al. The roles of EZH2 in cancer and its inhibitors
Liontos et al. Systemic therapy in cervical cancer: 30 years in review
Gong et al. Regulation of NANOG in cancer cells
Guo et al. Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1
Li et al. Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy
Feng et al. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients
Er et al. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC)
Yan et al. LncRNA CCAT2 promoted osteosarcoma cell proliferation and invasion
Pei et al. miR-122-5p inhibits tumor cell proliferation and induces apoptosis by targeting MYC in gastric cancer cells
Li et al. Impact of Taurine on the proliferation and apoptosis of human cervical carcinoma cells and its mechanism
Li et al. p53 and P-glycoprotein influence chemoresistance in hepatocellular carcinoma
Thillai et al. Molecularly targeted therapy for advanced hepatocellular carcinoma-a drug development crisis?
Hou et al. miR-33a expression sensitizes Lgr5+ HCC-CSCs to doxorubicin via ABCA1
Chang et al. Amiodarone promotes cancer cell death through elevated truncated SRSF3 and downregulation of miR-224
CN110545820A (zh) 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
Wu et al. IFIT3: a crucial mediator in innate immunity and tumor progression with therapeutic implications
FI3762004T3 (fi) Kasvainten hoitaminen onkolyyttisen adenoviruksen ja CDK4/6-inhibiittorin yhdistelmällä
Shen et al. Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo
JP2024125139A5 (cg-RX-API-DMAC7.html)
Li et al. Anticancer effects of myricetin derivatives in non‐small cell lung cancer in vitro and in vivo
Wang et al. Tambulin targets histone deacetylase 1 inhibiting cell growth and inducing apoptosis in human lung squamous cell carcinoma
Alameddine et al. From sprouting angiogenesis to erythrocytes generation by cancer stem cells: evolving concepts in tumor microcirculation
Hashimoto et al. The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment
Wang et al. TRIM24 siRNA induced cell apoptosis and reduced cell viability in human nasopharyngeal carcinoma cells
Nakhjavani et al. Human lung carcinoma reaction against metabolic serum deficiency stress